ATLANTA, May 2 /PRNewswire-FirstCall/ -- Inhibitex, Inc. announced today that it will present at the 2006 Baird Growth Stock Conference on Tuesday, May 9, 2006 at 10:40 a.m. CT (11:40 a.m. ET) from the Four Seasons Hotel in Chicago. William D. Johnston, Ph.D., president and chief executive officer of Inhibitex, Inc. will provide an update on the company and its clinical development programs.
A live audio webcast of the presentation will be available on the “Investors” section of the company’s website at www.inhibitex.com. The webcast will be archived and available on the Inhibitex website after the event for a period of 30 days.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. All of the company’s drug development programs are based on its proprietary MSCRAMM(R) protein platform. MSCRAMM proteins are located on the surface of pathogenic organisms and are responsible for the initiation and spread of infections. The company’s most advanced product candidates are Veronate(R) and Aurexis(R), for which the company has retained all worldwide rights. The company’s preclinical programs include a collaboration and joint development agreement with Dyax to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines. For additional information about the company, please visit www.inhibitex.com.
Inhibitex(R), MSCRAMM(R), Veronate(R) and Aurexis(R) are registered trademarks of Inhibitex, Inc.
CONTACTS: Inhibitex, Inc. Russell H. Plumb Chief Financial Officer (678) 746-1136 rplumb@inhibitex.com Laura Perry (Investors) Stern Investor Relations, Inc. (212) 362-1200 laura@sternir.com
Inhibitex, Inc.
CONTACT: Russell H. Plumb, Chief Financial Officer of Inhibitex, Inc.,+1-678-746-1136, or rplumb@inhibitex.com; or Investors, Laura Perry ofStern Investor Relations, Inc., +1-212-362-1200, or laura@sternir.com
Web site: http://www.inhibitex.com//
